Clinical efficacy and safety of linezolid in intensive care unit patients  

作　　者：Aijia Ma Meiling Dong Jiangli Cheng Xuelian Liao Wei Dong Chang Liu Chenggong Hu Jing Yang Yan Kang 

机构地区：[1]Department of Critical Care Medicine,West China Hospital of Sichuan University,Chengdu,Sichuan 610041,China

出　　处：《Journal of Intensive Medicine》2023年第1期65-72,共8页重症医学（英文）

基　　金：The relevant works were supported by grants from the horizontal project of West China Hospital of Sichuan University(Grant No.321190602).

摘　　要：Background:To characterize the population of critically ill patients and infections treated with linezolid in the intensive care unit(ICU),and to evaluate the clinical efficacy and safety of linezolid therapy.Methods::This multi-center,observational,real-world study was conducted across 52 hospitals between June 9,2018,and December 28,2019.Patients who met the following inclusion criteria were included:(1)admitted to the ICU,(2)of any age group,and(3)having a clinical or laboratory diagnosis of a Gram-positive bacterial infection.Clinical efficacy was categorized as success(cured or improved),failed,or non-evaluable.Adverse events and serious adverse events were recorded during treatment.Results::A total of 366 ICU patients who met the inclusion criteria were evaluated.Linezolid was used as second-and first-line treatment in 232(63.4%)and 134(36.6%)patients,respectively.The most common isolated strain was Staphylococcus aureus(methicillin-resistant Staphylococcus aureus:n=37/119,31.1%;methicillin-susceptible Staphylococcus aureus:n=15/119,12.6%);this was followed by Enterococci(vancomycin-resistant Enterococci:n=8/119,6.7%;vancomycin-susceptible Enterococci:n=11/119,9.2%)and Streptococcus pneumoniae(multidrug-resistant:n=4/119,3.4%;non-multidrug resistant:n=2/119,1.7%).The main infection sites where pathogens were detected included the lung(n=216/366,59.6%),skin and soft tissue(n=104/366,28.4%),and blood(n=50/366,13.7%).Clinical success was achieved in 301(82.2%)patients;34(9.3%)were cured and 267(73.0%)improved;treatment failure and non-evaluable outcomes were observed in 29(7.9%)in 36(9.8%)patients,respectively.Linezolid-related adverse events were reported in 8(2.2%)patients.No treatment-related serious adverse events were reported.Conclusions::Based on real-world results,linezolid was found to be effective and safe in the treatment of Gram-positive bacterial infections in critically ill patients.

关 键 词：Intensive care unit LINEZOLID Real-world study Gram-positive bacterial infection 

分 类 号：R473[医药卫生—护理学]